Summary
The National Institutes of Health (NIH) is soliciting research grant applications under a Phased Innovation Award (R61/R33) mechanism to enhance mechanistic research on precision probiotic therapies. The R61 phase supports milestone-driven exploratory research, while the R33 phase supports expanded development contingent on meeting R61 milestones. Clinical trials are optional under this announcement. The opportunity is a Program Announcement with Review (PAR), number PAR-25-211, open for multiple submission cycles through June 2027.